CN113180008A - FibroTouch-based non-alcoholic fatty liver disease rat model and manufacturing and detecting methods thereof - Google Patents
FibroTouch-based non-alcoholic fatty liver disease rat model and manufacturing and detecting methods thereof Download PDFInfo
- Publication number
- CN113180008A CN113180008A CN202110522163.6A CN202110522163A CN113180008A CN 113180008 A CN113180008 A CN 113180008A CN 202110522163 A CN202110522163 A CN 202110522163A CN 113180008 A CN113180008 A CN 113180008A
- Authority
- CN
- China
- Prior art keywords
- value
- rat
- fibrotouch
- feeding
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 30
- 238000011552 rat model Methods 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 title abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims abstract description 11
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 239000008280 blood Substances 0.000 claims abstract description 8
- 210000004369 blood Anatomy 0.000 claims abstract description 8
- 230000037396 body weight Effects 0.000 claims abstract description 8
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 238000001514 detection method Methods 0.000 claims description 27
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 13
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 13
- 208000004930 Fatty Liver Diseases 0.000 claims description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
- 208000010706 fatty liver disease Diseases 0.000 claims description 12
- 238000002372 labelling Methods 0.000 claims description 12
- 210000004185 liver Anatomy 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000005070 sampling Methods 0.000 claims description 8
- 238000005516 engineering process Methods 0.000 claims description 7
- 235000012000 cholesterol Nutrition 0.000 claims description 6
- 230000003176 fibrotic effect Effects 0.000 claims description 6
- 230000006698 induction Effects 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 4
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 4
- 229940109239 creatinine Drugs 0.000 claims description 4
- 238000007405 data analysis Methods 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000003902 lesion Effects 0.000 abstract description 2
- 230000003908 liver function Effects 0.000 abstract description 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 description 5
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 5
- 238000010586 diagram Methods 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/25—Animals on a special diet
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a FibroTouch-based non-alcoholic fatty liver disease rat model and a manufacturing and detecting method thereof, wherein the model comprises a plurality of mature rat individuals, the selected rat individuals are cultured in the same batch and have the same culture conditions, the body length and the body weight of the selected rat individuals are approximately the same and are healthy and disease-free, the conversion coefficient of the body weight coefficient is 0.018, the body weight coefficient is (Kg)/high (m)2, the conversion coefficient is (the body weight coefficient of the rat individuals/the body weight coefficient of an adult group), and the selected rat individuals are grouped according to male and female. The invention detects LSM and UAP values of NAFLD patients through Fibrotouch, and combines indexes such as liver function, blood fat and blood sugar, BMI and the like, thereby more accurately judging liver fibrosis and adiposis lesion degrees of NAFLD patients, being beneficial to actively intervening disease progress, and having obvious application value in clinical use.
Description
Technical Field
The invention relates to the technical field of medical detection tests, in particular to a non-alcoholic fatty liver disease rat model based on FibroTouch and a manufacturing and detecting method thereof.
Background
Non-alcoholic fatty liver disease (NAFLD) refers to the clinical pathological syndrome characterized mainly by excessive fat deposition in liver cells due to the exclusion of alcohol and other definite liver damage factors, and acquired metabolic stress liver damage closely related to insulin resistance and genetic susceptibility. The liver cirrhosis disease comprises Simple Fatty Liver (SFL), non-alcoholic steatohepatitis (NASH) and relative liver cirrhosis, the prevalence rate of NAFLD of a common adult is 10-30%, wherein NASH accounts for 10-20%, the incidence rate of liver cirrhosis in 10 years of the NASH is up to 25%, and the harm of the non-alcoholic steatohepatitis to human health is still increased continuously;
at present, NAFLD diagnosis in many areas still mainly depends on invasive liver tissue biopsy, but because of numerous pathogenic people, invasive operation, high cost and other factors, large-scale development is difficult in China, so that considerable difficulty is brought to NAFLD diagnosis, and patients probably lose the best treatment time, therefore, in order to solve the problems, a rat model of nonalcoholic fatty liver disease based on FibroTouch and a manufacturing and detection method are provided.
Disclosure of Invention
The invention aims to solve the defects in the prior art and provides a FibroTouch-based non-alcoholic fatty liver disease rat model and a manufacturing and detecting method thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
the non-alcoholic fatty liver disease rat model based on FibroTouch comprises a plurality of mature rat individuals, the selected rat individuals are cultured in the same batch and have the same culture conditions, the body length and the body weight of the selected rat individuals are approximately the same and are healthy and disease-free, the conversion coefficient of the weight coefficient is 0.018, the weight coefficient is (Kg)/body high (m)2, the conversion coefficient is (the weight coefficient of the rat individuals/the weight coefficient of an adult group), and the selected rat individuals are grouped according to male and female.
The preparation method of the rat model of the non-alcoholic fatty liver disease based on FibroTouch comprises two steps of grouping and labeling and feeding induction;
the packet labeling step comprises: dividing the female rat individual group and the male rat individual group into a normal feeding group and a sample feeding group according to the proportion of 1/4 to 3/4, and carrying out first part labeling on the sample feeding group of 3/4 and carrying out second part labeling on the normal feeding group of 1/4;
the feeding induction step comprises:
3): the normal feeding group and the sample adding feeding group both adopt basic feed as main feeding materials, wherein the content of the basic feeding materials in the normal feeding group is 100 percent, the content of the basic feeding materials in the sample adding feeding group is 75-80 percent, the sample adding components comprise lard and cholesterol, the total content of the sample adding components is 15-20 percent, and the content ratio of the lard to the cholesterol is 5: 1;
4): the normal feeding group and the sample adding feeding group are both placed in the same environment and grow for a period of time according to the same feeding amount and feeding time, and each individual rat is in an individual growth space.
The detection method of the rat model of the non-alcoholic fatty liver disease based on FibroTouch comprises four parts of sampling and marking, Fibrotouch technical detection, biochemical index detection and parameter data analysis and comparison:
s1: sampling and marking: sampling livers of each individual rat of the normal feeding group and the sample adding feeding group, and marking according to the sampled individual labels;
s2: detection by a Fibrotouch technology: detecting each liver sample by using a Fibrotouch inspection technology to detect an LSM value and a UAP value;
s3: and (3) biochemical index detection: performing biochemical index detection on the liver samples in the S2 part, wherein the detection direction of each liver sample corresponds to the LSM value and the UAP value, and the biochemical index detection parameters comprise ALT, AST, creatinine, TC, TG, HDL-C, LDL-C, fasting blood glucose and BMI;
s4: analyzing and comparing parameter data: and (4) establishing an independent table by combining the LSM value, the UAP value and the biochemical index detection parameter in the S3 part, and calculating a median value according to statistics.
Preferably, in S1, the test result shows that the value is rat actual value/0.018 in conversion units of a reduced coefficient of 0.018.
Preferably, in the step S2, the LSM value < 7.3 is defined as a non-fibrotic period (F0-F1), the LSM value between 7.3-9.7 kPa is defined as a mild fibrotic period (F2), the LSM value between 9.7-12.4 kPa is defined as a hepatic fibrosis period (F2-F3), the LSM value between 12.4-17.5 kPa is defined as a hepatic cirrhosis compensation period (F3-F4), the LSM value > 17.5kPa is defined as a hepatic cirrhosis decompensation period (F4), the UAP value < 240dB/m is defined as no steatosis (grade 0), the UAP value up to 265dB is defined as mild fatty liver (grade 1), the UAP value up to 295dB/m is defined as moderate fatty liver (grade 2), and the UAP value > 295dB/m is defined as severe fatty liver (grade 3).
The invention provides a rat model of non-alcoholic fatty liver disease based on FibroTouch and a manufacturing and detecting method thereof, which have the beneficial effects that:
1. in the scheme, the FibroTouch technology is used for detection, and the detection result is converted into the change on the numerical value, so that on one hand, the doctor can clearly judge the development of the disease, and on the other hand, the self recognition of the patient and the subsequent review and comparative analysis can be deepened;
2. in the scheme, rat individuals are used for replacing experimental detection objects, and big data analysis and comparison are carried out through a plurality of detected data, so that the effective rate of fatty liver diagnosis can be obtained, the disease progress can be actively intervened, and the method has obvious application value in clinical use
Drawings
FIG. 1 is a schematic structural diagram of a rat model of non-alcoholic fatty liver disease based on FibroTouch according to the present invention;
FIG. 2 is a LSM and UAP correlation scattergram in the detection method of the rat model of non-alcoholic fatty liver disease based on FibroTouch provided by the invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments.
In the description of the present invention, it is to be understood that the terms "upper", "lower", "front", "rear", "left", "right", "top", "bottom", "inner", "outer", and the like, indicate orientations or positional relationships based on the orientations or positional relationships shown in the drawings, are merely for convenience in describing the present invention and simplifying the description, and do not indicate or imply that the device or element being referred to must have a particular orientation, be constructed and operated in a particular orientation, and thus, should not be construed as limiting the present invention.
Referring to fig. 1, a method for manufacturing a non-alcoholic fatty liver disease rat model and a rat model based on FibroTouch includes a plurality of mature rat individuals, and is characterized in that the selected rat individuals are cultured in the same batch and have the same culture conditions, the body length and the body weight of the selected rat individuals are approximately the same and are healthy and disease-free, the conversion coefficient of the weight coefficient is 0.018, the weight coefficient is (Kg)/body height (m)2), the conversion coefficient is (the weight coefficient of the rat individuals/the weight coefficient of the adult group), and the selected rat individuals are grouped according to sex;
the method comprises two steps of grouping labeling and feeding induction;
the packet labeling step comprises: dividing the female rat individual group and the male rat individual group into a normal feeding group and a sample feeding group according to the proportion of 1/4 to 3/4, and carrying out first part labeling on the sample feeding group of 3/4 and carrying out second part labeling on the normal feeding group of 1/4;
the feeding induction step comprises:
5): the normal feeding group and the sample adding feeding group both adopt basic feed as main feeding materials, wherein the content of the basic feeding materials in the normal feeding group is 100 percent, the content of the basic feeding materials in the sample adding feeding group is 75-80 percent, the sample adding components comprise lard and cholesterol, the total content of the sample adding components is 15-20 percent, and the content ratio of the lard to the cholesterol is 5: 1;
6): the normal feeding group and the sample adding feeding group are both placed in the same environment and grow for a period of time according to the same feeding amount and feeding time, and each individual rat is in an individual growth space.
The present invention includes embodiments
In the first embodiment:
s1: sampling and marking: sampling livers of each individual rat of the normal feeding group and the sample adding feeding group, and marking according to the sampled individual labels;
s2: detection by a Fibrotouch technology: detecting each liver sample by using a Fibrotouch inspection technology to detect an LSM value and a UAP value;
further, in S1, the test shows that the value is rat actual value/0.018 in conversion units of a reduced coefficient of 0.018;
in step S2, LSM value < 7.3 is defined as a non-fibrotic period (F0-F1), LSM value between 7.3-9.7 kPa is defined as a mild fibrotic period (F2), LSM value between 9.7-12.4 kPa is defined as a hepatic fibrosis period (F2-F3), LSM value between 12.4-17.5 kPa is defined as a hepatic cirrhosis compensation period (F3-F4), LSM value > 17.5kPa is defined as a hepatic cirrhosis decompensation period (F4), UAP value < 240dB/m is defined as a non-fatty period (grade 0), UAP value up to 265dB is defined as a mild fatty liver (grade 1), UAP value up to 295dB/m is defined as a moderate fatty liver (grade 2), and UAP value > 295dB/m is defined as a severe fatty liver (grade 3).
LSM and UAP values were determined for each individual rat, and the table was generated as follows:
with reference to fig. 2, the following conclusions can be drawn: and (3) making a scatter diagram according to the LSM and UAP values of the patient, finding that the scatter diagrams of the LSM and UAP values are randomly distributed, and detecting the result more effectively.
In the second embodiment: the difference from the first embodiment is that:
s3: and (3) biochemical index detection: performing biochemical index detection on the liver samples in the S2 part, wherein the detection direction of each liver sample corresponds to the LSM value and the UAP value, and the biochemical index detection parameters comprise ALT, AST, creatinine, TC, TG, HDL-C, LDL-C, fasting blood glucose and BMI;
s4: analyzing and comparing parameter data: and (4) establishing an independent table by combining the LSM value, the UAP value and the biochemical index detection parameter in the S3 part, and calculating a median value according to statistics.
The following table was produced from the data:
in summary, the following steps: the method combines the numerical values of a plurality of tables to display that the effective rate of fibrouch test and diagnosis of hepatic fibrosis is 87.5 percent, the effective rate of fatty liver test and diagnosis is 92.8 percent, and the method has higher test efficiency, compares the LSM value of a hepatic fibrosis group without hepatic fibrosis and the numerical values of indexes related to hepatic fibrosis group ALT, AST, creatinine, TC, TG, HDL-C, LDL-C, fasting blood glucose and BMI, compares various data parameters to obtain the LSM and UAP values of a patient NAFLD (non-hepatic fibrosis) patient with fibrouch test, and combines the indexes of liver function, blood lipid, blood glucose, BMI and the like, thereby more accurately judging the liver fibrosis and fatty lesion degree of the patient NAFLD, being beneficial to actively intervening the disease progress and having obvious application value when being used clinically.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention should be equivalent or changed within the scope of the present invention.
Claims (5)
1. The non-alcoholic fatty liver disease rat model based on FibroTouch comprises a plurality of mature rat individuals, and is characterized in that the selected rat individuals are cultured in the same batch and have the same culture conditions, the body length and the body weight of the selected rat individuals are approximately the same and are healthy and disease-free, the conversion coefficient of the weight coefficient is 0.018, the weight coefficient is (Kg)/high (m)2, and the conversion coefficient is (the weight coefficient of the rat individuals/the weight coefficient of an adult group), and the selected rat individuals are grouped according to male and female.
2. The method for preparing a rat model of non-alcoholic fatty liver disease based on FibroTouch according to claim 1, comprising two steps of grouping and labeling and feeding induction;
the packet labeling step comprises: dividing the female rat individual group and the male rat individual group into a normal feeding group and a sample feeding group according to the proportion of 1/4 to 3/4, and carrying out first part labeling on the sample feeding group of 3/4 and carrying out second part labeling on the normal feeding group of 1/4;
the feeding induction step comprises:
1): the normal feeding group and the sample adding feeding group both adopt basic feed as main feeding materials, wherein the content of the basic feeding materials in the normal feeding group is 100 percent, the content of the basic feeding materials in the sample adding feeding group is 75-80 percent, the sample adding components comprise lard and cholesterol, the total content of the sample adding components is 15-20 percent, and the content ratio of the lard to the cholesterol is 5: 1;
2): the normal feeding group and the sample adding feeding group are both placed in the same environment and grow for a period of time according to the same feeding amount and feeding time, and each individual rat is in an individual growth space.
3. The method for testing a rat model with non-alcoholic fatty liver disease based on FibroTouch as claimed in claim 1 and claim 2, which comprises four parts of sampling mark, Fibrotouch technical test, biochemical index test and parameter data analysis and comparison:
s1: sampling and marking: sampling livers of each individual rat of the normal feeding group and the sample adding feeding group, and marking according to the sampled individual labels;
s2: detection by a Fibrotouch technology: detecting each liver sample by using a Fibrotouch inspection technology to detect an LSM value and a UAP value;
s3: and (3) biochemical index detection: performing biochemical index detection on the liver samples in the S2 part, wherein the detection direction of each liver sample corresponds to the LSM value and the UAP value, and the biochemical index detection parameters comprise ALT, AST, creatinine, TC, TG, HDL-C, LDL-C, fasting blood glucose and BMI;
s4: analyzing and comparing parameter data: and (4) establishing an independent table by combining the LSM value, the UAP value and the biochemical index detection parameter in the S3 part, and calculating a median value according to statistics.
4. The method of claim 3, wherein in step S1, the value measured and displayed by the conversion coefficient of 0.018 is rat actual value/0.018.
5. The method of claim 3, wherein in step S2, LSM value < 7.3 is defined as a non-fibrotic period (F0-F1), LSM value between 7.3-9.7 kPa is defined as a mild fibrotic period (F2), LSM value between 9.7-12.4 kPa is defined as a hepatic fibrosis period (F2-F3), LSM value between 12.4-17.5 kPa is defined as a hepatic cirrhosis compensation period (F3-F4), LSM value > 17.5kPa is defined as a hepatic cirrhosis decompensation period (F4), UAP value < 240dB/m is defined as non-fatty period (0), UAP value up to 265dB is defined as a mild fatty liver (1), UAP value up to 295dB is defined as moderate fatty liver (2), and UAP value up to 295dB/m is defined as severe fatty liver (3 dB).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110522163.6A CN113180008A (en) | 2021-05-13 | 2021-05-13 | FibroTouch-based non-alcoholic fatty liver disease rat model and manufacturing and detecting methods thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110522163.6A CN113180008A (en) | 2021-05-13 | 2021-05-13 | FibroTouch-based non-alcoholic fatty liver disease rat model and manufacturing and detecting methods thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113180008A true CN113180008A (en) | 2021-07-30 |
Family
ID=76981456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110522163.6A Pending CN113180008A (en) | 2021-05-13 | 2021-05-13 | FibroTouch-based non-alcoholic fatty liver disease rat model and manufacturing and detecting methods thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113180008A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103614415A (en) * | 2013-11-27 | 2014-03-05 | 苏州同善生物科技有限公司 | Method for establishing obese rat animal model based on CRISPR (clustered regularly interspaced short palindromic repeat) gene knockout technology |
| CN104509705A (en) * | 2013-09-29 | 2015-04-15 | 中国人民解放军南京军区南京总医院 | Application of composite high-fat forage to construct non-alcoholic fatty liver disease rat model |
| CN106362092A (en) * | 2016-10-26 | 2017-02-01 | 河北医科大学第三医院 | Qi supplementing and blood circulation activating traditional Chinese medicine composition for treating liver fibrosis |
| CN107148941A (en) * | 2017-04-07 | 2017-09-12 | 安徽农业大学 | A kind of modeling method of hyperlipemia model |
| CN107197823A (en) * | 2017-06-20 | 2017-09-26 | 遵义医学院 | A kind of Establishment of Rat Model method of NASH |
| CN111789078A (en) * | 2020-07-20 | 2020-10-20 | 北京航空航天大学 | Method for establishing rat non-obese non-alcoholic fatty liver disease model |
-
2021
- 2021-05-13 CN CN202110522163.6A patent/CN113180008A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104509705A (en) * | 2013-09-29 | 2015-04-15 | 中国人民解放军南京军区南京总医院 | Application of composite high-fat forage to construct non-alcoholic fatty liver disease rat model |
| CN103614415A (en) * | 2013-11-27 | 2014-03-05 | 苏州同善生物科技有限公司 | Method for establishing obese rat animal model based on CRISPR (clustered regularly interspaced short palindromic repeat) gene knockout technology |
| CN106362092A (en) * | 2016-10-26 | 2017-02-01 | 河北医科大学第三医院 | Qi supplementing and blood circulation activating traditional Chinese medicine composition for treating liver fibrosis |
| CN107148941A (en) * | 2017-04-07 | 2017-09-12 | 安徽农业大学 | A kind of modeling method of hyperlipemia model |
| CN107197823A (en) * | 2017-06-20 | 2017-09-26 | 遵义医学院 | A kind of Establishment of Rat Model method of NASH |
| CN111789078A (en) * | 2020-07-20 | 2020-10-20 | 北京航空航天大学 | Method for establishing rat non-obese non-alcoholic fatty liver disease model |
Non-Patent Citations (2)
| Title |
|---|
| 张晓静等: "FibroTouch 技术在诊断非酒精性脂肪性肝病患者肝脂肪变程度中的应用", 《临床医学》 * |
| 陈剑明等: "高脂饮食诱导非酒精性脂肪肝大鼠模型的实验研究", 《中华中医药学刊》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Samaranayake et al. | Factors affecting the phospholipase activity of Candida species in vitro | |
| Aspiroz et al. | Isolation of Malassezia globosa and M. sympodialis from patients with pityriasis versicolor in Spain | |
| CN101914483B (en) | Liquid-based thin-layer cell preservation solution and use thereof | |
| Davies | Mycological tests and onychomycosis | |
| CN105420405A (en) | Bovine serum microRNA molecular marker of milk cow fatty liver disease and milk cow perinatal period-associated metabolic disease | |
| WO2023098678A1 (en) | High-protein saccharomyces cerevisiae and application thereof | |
| Mansour et al. | Cut-off values for waist circumference in rural Iraqi adults for the diagnosis of metabolic syndrome | |
| Comaish et al. | Candidiasis—serology and diagnosis | |
| CN113180008A (en) | FibroTouch-based non-alcoholic fatty liver disease rat model and manufacturing and detecting methods thereof | |
| CN101886111A (en) | Fungus rapid culture, identification and susceptibility detection kit and detection method thereof | |
| Bonns | A preliminary study of Claviceps purpurea in culture | |
| Woo et al. | Nutritional status of healthy, active, Chinese elderly | |
| Jitsurong et al. | New milk medium for germ tube and chlamydoconidia production by Candida albicans | |
| CN104789488A (en) | Lactobacillus rhamnosus having cholesterol lowering effect, and uses thereof | |
| CN101555516A (en) | Candida albicans rapid identification and cultivation susceptibility test kit and test method | |
| CN109136151A (en) | A kind of composite plant Lemonal and its application with reduction blood glucose function | |
| CN108567845A (en) | A kind of biofermentation products and preparation method thereof of prevention colitis | |
| CN112695078A (en) | Method for screening hyphal Candida albicans virulence related gene | |
| CN102037929A (en) | Method for constructing animal infection model of streptococcus suis type 2 | |
| CN109259202A (en) | The method for preparing blood sugar reducing food using the solid state transformed Chinese yam of tremella and corn | |
| Patriota et al. | Echocardiography and analysis of subclinical cardiovascular diseases in indigenous people living in different degrees of urbanization: project of atherosclerosis among indigenous populations (Pai) | |
| LU504512B1 (en) | Prognostic risk assessment system for severe liver fibrosis related to metabolic associated fatty liver disease and its application | |
| CN201678682U (en) | Susceptibility test kit capable of rapidly identifying pathogenic fungi through culturing | |
| CN105274242B (en) | A method of for non-treatment and detection mitochondria tRNALeu (UUR) 3253T > C mutation of non-diagnostic purpose | |
| Lee et al. | Some clinical indices of nutrition and health status among elderly Kentucky residents volunteering to be surveyed: comparison by sociological factors, life styles and health characteristics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210730 |
|
| RJ01 | Rejection of invention patent application after publication |